ATYR aTyr Pharma, Inc.
$0.12▼ -19.17%
Healthcare
Other
After hours
$0.12▲ +0.24%
Oct 27, 5:43 PM ET
Volume 8.19M
Avg Volume (10D) 1.95M
Key Metrics & Fundamentals
Market Cap
$12.16M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.10 - 1.11
% vs 50 MA
-64.90%
% vs 200 MA
-79.78%
RSI-14
10.6
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.41
Free Cash Flow
-$9.42M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$10.48M
COGS
–
Operating Exp
$10.88M
Operating Income
-$10.88M
EBIT
-$10.88M
Pretax Income
-$10.31M
Net Income
-$10.31M
EPS (Diluted)
-0.11
Price & Volume History
Loading chart…
Recent News
aTyr Pharma Announces One-for-40 Reverse Stock Split
GlobeNewswire · Oct 27, 2026 9:00 AM ET
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
GlobeNewswire · Oct 19, 2026 7:00 AM ET
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
GlobeNewswire · Oct 13, 2026 8:00 AM ET
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
Benzinga · Sep 24, 2026 1:31 PM ET
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis
InvestorsHub · Sep 24, 2026 10:59 AM ET
BC-Most Active Stocks
Associated Press · Sep 24, 2026 10:30 AM ET
Top Premarket Gainers
MT Newswires · Sep 24, 2026 7:06 AM ET
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
GlobeNewswire · Sep 24, 2026 6:00 AM ET
Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
PR Newswire · Sep 8, 2026 10:31 AM ET
aTyr Pharma Updates Timing of FDA Response for Planned Phase 3 Trial of Efzofitimod
MT Newswires · Sep 1, 2026 5:10 PM ET
Financial Overview - Income Statement
Quarterly
Sep 2025
See ATYR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.